Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Abilify Maintena, Aristada, Abilify Asimtufii, Abilify, Abilify MyCite, Aristada Initio
Synonyms :
aripiprazole
Class :
2nd generation Anti psychotics, Antimaniac agents
Brand Name :
Abilify Maintena, Aristada, Abilify Asimtufii, Abilify, Abilify MyCite, Aristada Initio
Synonyms :
aripiprazole
Class :
2nd generation Anti psychotics, Antimaniac agents
Dosage Forms & Strengths
Tablet, Ingestable event marker (IEM) sensor embedded (Abilify MyCite)
2mg
5mg
10mg
15mg
20mg
30mg
Abilify The MyCite system consists of the following elements:
The tablet contains an ingestible event marker (IEM) sensor
MyCite patch is a wearable sensor that sends information to a smartphone after detecting the signal from an IEM sensor after consumption.
A compatible smartphone is used to access the MyCite APP, a smartphone application (app) that shows patient information. Portal on the web enables medical staff and patients to share information.
Oral solution
1mg/ml
Oral disintegrating tablet
10mg
15mg
aripiprazole lauroxil [Aristada] injectable intramuscular suspension (extended release)
441mg in a prefilled syringe (aripiprazole 300mg)
662mg in a prefilled syringe (aripiprazole 450mg)
882mg in a prefilled syringe (aripiprazole 600mg)
1064mg in a prefilled syringe (aripiprazole 724mg)
Injectable intramuscular suspension with extended-release (Abilify Maintena)
Prefilled dual chamber syringe or 300mg/vial
400mg/vial or dual chamber syringe prefilled
Injectable Intramuscular suspension with extended-release aripiprazole lauroxil [Aristada Initio]
675mg/2.4mL prefilled syringe (aripiprazole 459mg)
Orally
Initial oral dosing of 10–15 mg/day; possible dosage increases of up to two weeks at every single dose strength; maximum oral dosing of 30 mg/day when given in tablet form; increased effectiveness above 15 mg/day not seen.
Abilify Maintena
First-time users of aripiprazole should start with 400 mg administered intramuscularly (IM) once monthly.
Before beginning therapy with Abilify Maintena, it is essential to determine whether you can take oral aripiprazole; this process may take up to two weeks.
After the initial injection, patients who have shown tolerance to aripiprazole should take 10 to 20 mg of the drug orally daily for 14 days.
Patients who are stable or tolerant to aripiprazole receive 400 mg intramuscularly (IM) once per month.
The monthly dose should be administered only 26 days after the previous injection. Consider reducing the monthly dose to 300 mg if an adverse reaction occurs.
Aristada Initio (single intramuscular dose)
Aristada is recommended for the initial treatment of schizophrenia when taken with oral aripiprazole.
Aristada may be started with a single dosage or restarted with a single dose when a dose was skipped.
Aristada Initio therapy should only be started if aripiprazole oral solution tolerance has been established; this may take up to 2 weeks.
aripiprazole orally (PO) should be tolerated before starting Aristada intramuscularly (IM).Aristada Initio 675 mg intramuscularly with aripiprazole 30 mg orally.
Do not take more than one dosage of Aristada Initio at a time. The first Aristada extended-release intramuscular injection may be administered on the exact same day as Aristada Initio or up to 10 days later.
Aristada (intramuscular monthly once )
Tolerance should be established with oral aripiprazole before starting Aristada; properly evaluating tolerance may take up to 2 weeks.
Aristada's first dosage should be based on the present aripiprazole oral dose; coadminister aripiprazole for 21 days orally
10 mg/day orally: Administer 441 mg intramuscularly once a month
15 mg/day orally: 662 mg intramuscular once a month or 882 mg intramuscular every six weeks, or 1064 mg intramuscular every two months
≥20 mg/day orally: 882 mg intramuscularly once monthly
Abilify Asimtufii (intramuscular every two months)
aripiprazole has never been used
Before starting 960 mg intramuscularly every two months, evaluate oral aripiprazole for tolerability. Tolerability testing may take up to 2 weeks. For 14 days following the first injection, individuals with known aripiprazole tolerance should continue taking oral aripiprazole (10 to 20 mg/day) or other antipsychotics orally.
With oral antipsychotics, Administer the initial dosage in combination with oral aripiprazole 10-20 mg orally for 14 consecutive days. Another oral antipsychotic that is stable (and is known to tolerate aripiprazole): For 14 days, provide the initial injection along with an oral antipsychotic.
Patients on Abilify Maintena In patients taking Abilify Maintena (one monthly dose)
Take Abilify Asimtufii 960 mg once every two months instead of the next scheduled injection of Abilify Maintena.
Provide the first injection of Abilify Asimtufii instead of the second or subsequent dose of Abilify Maintena.
If the 960-mg Abilify Asimtufii dose causes unpleasant responses, the dosage may be reduced to 720 mg once every two months. Abilify Asimtufii may be given up to 2 weeks before or after the 2-month prescribed time point.
Orally
Initial dose of 15 mg/day orally; may be increased progressively; a maximum daily dose of 30 mg/day.
Adjunct to lithium or valproate:10 to 15 mg/day orally initially; 15 mg/day is the recommended daily dose; may be progressively increased; Do not exceed 30 mg/day.
Continue the stabilization dosage for up to 6 weeks; therapy beyond six weeks has not been investigated.
Abilify Maintena
Patients without prior exposure to aripiprazole should begin with a monthly 400 mg Intramuscular dose.
Only a healthcare expert should administer this medication through deep intramuscular injection into the deltoid or gluteal muscle.
Establish tolerance with aripiprazole orally before beginning Abilify Maintena medication; thoroughly evaluating tolerability may take up to 2 weeks.
In patients with known aripiprazole tolerance, continue aripiprazole orally (10 to 20 mg/day) or other oral antipsychotics for 14 days following the first injection.
Patients who are stable or tolerant to aripiprazole receive 400 mg intramuscularly (IM) once per month. Administer monthly dose no earlier than 26 days after the previous injection. Consider reducing the monthly dose to 300 mg if an adverse reaction occurs.
Abilify Asimtufii (intramuscular every two months)
Never consumed aripiprazole
Establish oral aripiprazole tolerability before initiating 960 mg Intramuscular every two months.
Up to two weeks may be required to assess tolerability in patients with known aripiprazole tolerance thoroughly; continue oral aripiprazole (10 to 20 mg/day) or other antipsychotics Orally for 14 days after the first injection.
Orally antipsychotic-treated
Administer the initial dose of oral aripiprazole along with 10 to 20 mg for 14 consecutive days. Known to tolerate aripiprazole and stable on another oral antipsychotic First injection along with oral antipsychotic medication for 14 consecutive days
Treatment with Abilify Maintena
Administration of Abilify Asimtufii 960 mg every two months instead of the next planned injection of Abilify Maintena (once monthly dose) is recommended for patients on Abilify Maintena. Administer the first injection of Abilify Asimtufii instead of the second or subsequent injection of Abilify Maintena.
If adverse reactions occur with Abilify Asimtufii 960 mg, the dosage may be reduced to 720 mg every two months.
May administer Abilify Asimtufii up to 2 weeks before or after the 2-month timepoint.
Initially, 2 to 5 mg/day orally; increased by 5 mg/day weekly whenever needed to a dosage range of 2 to 15 mg/day.
Dose Adjustments
Oral
Cytochrome-P 450 inhibitors and those with poor metabolism CYP2D6 poor metabolizers known: Administer half the usual dosage.
Poor metabolizers of CYP2D6 that utilize potent CYP3A4 inhibitors: Administer one-fourth of the prescribed dose (i.e., a 75% reduction).
Potent inhibitors of CYP2D6 or CYP3A4: Administer half the recommended dose Strong CYP3A4 inducers: twice the required dosage over 1-2 weeks.
Dosage Modifications (Abilify Maintena)
Poor metabolizers of CYP2D6: 300 mg Intramuscular
CYP2D6 poor metabolizers are taking a CYP3A4 inhibitor concurrently: 200 mg Intramuscular.
Patients taking 400 mg intramuscular
Strong CYP3A4 OR CYP2D6 inhibitors: 300 mg intramuscular
CYP3A4 And CYP2D6 inhibitors: 200 mg intramuscular
CYP3A4 inducers: Avoid usage
Patients taking 400 mg intramuscular
Strong CYP3A4 OR CYP2D6 inhibitors: 200 mg intramuscular
CYP3A4 And CYP2D6 inhibitors: 160 mg intramuscular
CYP3A4 inducers: Avoid usage
Dosage Modifications (Aristada)
There are no dose adjustments if CYP450 modulators are administered for less than two weeks.
Potent CYP3A4 inhibitor for more than two weeks
Lower the dosage to the next lowest strength. If 441 mg is tolerated, no dose change is required. Poor metabolizers of CYP2D6: Reduce the dose from 662 mg, 882 mg, or 1064 mg to 441 mg; if tolerated, there is no need to modify the dosage for individuals using 441 mg.
For more than two weeks, a potent CYP2D6 inhibitor was used:
Lower the dosage to the next lowest strength. If 441 mg is tolerated, no dose change is required.
Poor CYP2D6 metabolizers: There is no need to alter the dosage.
Both powerful CYP3A4 and CYP2D6 inhibitors were used for over two weeks:
Patients taking 662 mg, 882 mg, or 1064 mg should avoid using it.
If 441 mg is tolerated, no dose change is required.
CYP3A4 inducers for more than two weeks:
There is no need to change the dosage to 662 mg, 882 mg, or 1064 mg. Increase the dosage from 441 mg to 662 mg.
Dosage Modifications (Aristada inito)
Poor CYP2D6 metabolizers, potent CYP3A4 inhibitors, and potent CYP3A4 inducers: Avoid using
Hepatic Impairment
Mild-to-severe (Child-Pugh score 5-15): There is no need for a dose change.
Renal Impairment
Mild-to-severe (GFR 15-90 mL/min): No dose changes are required.
Dosage Modifications (Abilify Asimtufii)
Poor CYP2D6 metabolizers
Poor CYP2D6 metabolizers: 720 mg every two months
Avoid usage if you are a known CYP2D6-poor metabolizer taking a CYP3A4 inhibitor.
Coadministration of CYP2D6 inhibitors-Patients on 960 mg should be reduced to 720 mg every two months.
Coadministration of CYP3A4 inhibitors-Patients on 960 mg should be reduced to 720 mg every two months.
Patients using 960 mg: Avoid coadministration with strong CYP2D6 and CY3A4 inhibitors.
Patients using 960 mg should avoid coadministration with potent CY3A4 inducers.
Dosage Forms & Strengths
Tablet
2mg
5mg
10mg
15mg
20mg
30mg
Oral solution
1mg/mL
Tablet, orally disintegrating
10mg
15mg
<13 years: Safety and efficacy not established
13 to 17 years: Initial oral dosage of 2 mg/day, followed by a rise to 5 mg/day after two days, and then, after an additional two days, a possible increase to the recommended dose of 10 mg/day;
maintenance dose: 10 to 30 mg/day
10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day
10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day
<6 years: Safety and efficacy not established
6 to 17 years:
Initial dose: 2 mg/day orally; increase progressively at 1-week intervals to 5 mg/day; may gradually increase whenever needed to 10 mg/day or higher; maximum dose: 15 mg/day
<6 years: Safety and efficacy not established
6 to 18years (<50 kg):
Start with 2 mg/day orally (PO), increasing to 5 mg/day after two days. If patients are not experiencing good suppression of tics at 5 mg/day, they may escalate to 10 mg/day. Dosage adjustments should be made progressively at no less than one-week intervals.
6 to 18years (>50 kg):
Take 2 mg orally daily for two days, 5 mg for five days, and 10 mg on day 8. The daily dosage can be increased to 20 mg for patients who do not attain optimal tic control. Dosage adjustments should be made progressively in 5 mg/day increments at no less than one-week intervals.
Dose Adjustments
Poor metabolizers and cytochrome-P 450 inhibitors
Poor metabolizers of CYP2D6: Administer half of the suggested dosage.
Known CYP2D6 poor metabolizers concurrently receiving potent CYP3A4 inhibitors: Administer one-fourth of the prescribed dose (i.e., a 75% reduction).
Potent inhibitors of CYP2D6 or CYP3A4: Administer half the suggested
dose
Strong CYP2D6 AND CYP3A4 inhibitors: Administer a quarter of the recommended dose (or a 75% reduction in dosage).
Strong inducers of CYP3A4: double the recommended dose over 1 to 2 weeks.
Refer adult dosing
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the serum concentration when combined with aripiprazole
may diminish the serum concentration when combined with aripiprazole
may diminish the serum concentration when combined with aripiprazole
may diminish the serum concentration when combined with aripiprazole
may diminish the serum concentration when combined with aripiprazole
may decrease the therapeutic effect of Antipsychotic Agents
may decrease the therapeutic effect of Antipsychotic Agents
may decrease the therapeutic effect of Antipsychotic Agents
may decrease the therapeutic effect of Antipsychotic Agents
may decrease the therapeutic effect of Antipsychotic Agents
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the toxic effect of Seizure Threshold Lowering Potential agents
may increase the toxic effect of the Seizure Threshold, Lowering Potential agents
may increase the arrhythmogenic effect of Antipsychotic Agents
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
calcium, magnesium, potassium and sodium oxybateÂ
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may decrease the metabolism when combined
may diminish the serum concentration of CYP3A4 Inducers
may enhance the serum concentration of CYP3A4 Inhibitors
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the toxic effect of Antipsychotic Agents
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the toxic effect of Antipsychotic Agents
may increase the CNS depressant effect of CNS Depressants
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
QTc interval increases on taking aripiprazole and lenvatinib together. Avoid or take an alternate drug
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, there may be an increase in the QTC interval
It may enhance QTc interval when combined with pentamidine
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
It may enhance sedation when combined with tramadol
may increase the neurotoxic effect of Antipsychotic Agents
may increase the neurotoxic effect of Antipsychotic Agents
may increase the toxic effect of Antipsychotic Agents
may increase the toxic effect of Antipsychotic Agents
may increase the toxic effect of Antipsychotic Agents
may increase the toxic effect of Antipsychotic Agents
may increase the toxic effect of Antipsychotic Agents
may increase the CNS depressant effect of CNS Depressants
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may increase the hypotensive effect of Antipsychotic Agents
may increase the hypotensive effect of Antipsychotic Agents
may increase the hypotensive effect of Antipsychotic Agents
may increase the hypotensive effect of Antipsychotic Agents
may increase the hypotensive effect of Antipsychotic Agents
may increase the toxic effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
it may diminish the therapeutic efficacy when combined with castor oil
may enhance the concentration of serum when combined with aripiprazole
may enhance the concentration of serum when combined with aripiprazole
may enhance the concentration of serum when combined with aripiprazole
may enhance the concentration of serum when combined with aripiprazole
may enhance the concentration of serum when combined with aripiprazole
aripiprazole's orthostatic hypotensive effects may be enhanced by levobetaxolol
The potential for increased CNS depression risk or seriousness occurs when aripiprazole is used together with pinazepam
When aripiprazole is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with aripiprazole, There is a risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when aripiprazole is used together with fencamfamin
Combining tegafur with aripiprazole can reduce tegafur’s metabolism
When aripiprazole is used together with fluconazole, this leads to reduction in the aripiprazole metabolism
When chlordiazepoxide is used together with aripiprazole, this leads to enhanced risk or seriousness of CNS depression
When aripiprazole is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
may diminish the therapeutic effect of the drug
When ponesimod is used together with aripiprazole, this leads to enhanced risk or seriousness of bradycardia
When ariprazole is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When aripiprazole is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of aripiprazole
When aripiprazole is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
When emylcamate is used together with aripiprazole, this leads to enhanced risk or seriousness of CNS depression
When azatadine is used together with aripiprazole, this leads to enhanced risk or seriousness of adverse events
When indisulam is used together with aripiprazole, this leads to a reduction in aripiprazole metabolism
the therapeutic efficacy of aripiprazole may be diminished when used in combination with ambenonium
when combined with cimetropium, there is an increased risk or severity of adverse effects with aripiprazole
when combined with indalpine, the metabolism of aripiprazole may be reduced
When aripiprazole is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
aripiprazole: it may increase the risk of hypotension with caroverine
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with aripiprazole
the hazard or seriousness of QTc prolongation can be heightened when aripiprazole is combined with digitoxin
the effect of aripiprazole is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
CYP2D6 inhibitors increase the concentration of aripiprazole
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may increase the risk or severity of gastrointestinal bleeding when combined
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may decrease the therapeutic efficacy when combined
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the risk of adverse effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may diminish the excretion rate of each other when combined
may have an increased effect of orthostatic hypotension when combined with Aripiprazole
the therapeutic activity of aripiprazole may be reduced
the risk of CNS depression may be increased
the therapeutic effect of aripiprazole may be reduced
an alteration in the therapeutic activity of either of the drugs may be seen
the rate of metabolism of aripiprazole may be reduced
the rate of metabolism of aripiprazole may be reduced
the risk of adverse effects may be increased
the risk of CNS depression may be increased
When aripiprazole is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Actions and Spectrum
The exact mechanism of action of aripiprazole is unknown and complicated. The fact that it functions as an antagonist at serotonin 5-HT2A receptors and a partial agonist at dopamine D2 and serotonin 5-HT1A receptors adds to its effectiveness in treating the symptoms of bipolar disorder and schizophrenia. It also has an impact on other neurotransmitter systems, such as histamine receptors and noradrenaline.
The spectrum of activity of aripiprazole includes the treatment of schizophrenia, bipolar disorder (both mania and depression) and major depressive disorder.
Frequency defined
>10%
Headache (27%)
Insomnia (18%)
Weight gain (8-30%)
Agitation (19%)
1-10%
Dyspepsia (9%)
Fatigue (6%)
Tremor (6%)
Pain (3%)
Rash
Rhinitis
Orthostatic hypotension (1-5%)
<1%
Autonomic instability
Hyperpyrexia
Altered mental status
Dysphagia
Muscle rigidity
Seizure
Black box warning
Aripiprazole’s black box warning alerts physicians to a higher risk of death in older patients experiencing psychosis associated to dementia.
Contraindications/caution
Contraindications:
Caution:
Pregnancy/Lactation
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is known
Pregnancy category:
Pharmacodynamics:
Pharmacodynamics of aripiprazole is in relation to its action on the brain dopamine and serotonin neurotransmitters. It acts as a partial agonist at dopamine D2 receptors which controls the movement, cognition and emotion. It acts as a partial agonist at serotonin 5-HT1A receptors which helps in mediating mood and anxiety. This partially activated behaviour can normalize dopamine activity and reduce the symptoms of psychosis.
Pharmacokinetics:
Absorption
Peak plasma concentrations are 3 to 5 hours.
Oral bioavailability- 87%
Distribution
aripiprazole is strongly protein-bound (more than 99%) to albumin and alpha-1-acid glycoprotein.
Metabolism
The CYP3A4 enzymes of the liver cleave aripiprazole into dehydroaripiprazole that is found as an ineffective metabolite in the system after being excreted through feces and urine.
Excretion and Elimination
The metabolites of aripiprazole are excreted in the urine and feces. The elimination half-life is approximately 75 hours.
Administration
It is administered orally in the form of tablets
Patient information leaflet
Generic Name: aripiprazole
Why do we use aripiprazole?
aripiprazole is a medication that is primarily used to treat several psychiatric conditions:
Schizophrenia: It is approved for schizophrenia treatment use in adults and adolescents greater than 13 years of age.
Bipolar disorder: The FDA approved aripiprazole to treat mania and mixed episodes commonly observed in young people with bipolar disorder. It is a non-selective and powerful monoamine-releasing agent which improves mood and consequently alleviates symptoms such as agitation, impulsivity, and irritability.
Autism spectrum disorder: In children (aged 6 to 17) and teens the medication aripiprazole was proved effective in decreasing irritability due to autism spectrum disorder.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
